Evidence map›Paper›PMID 35061841›Full record

ArticlePloS one2022

Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.

Davit Baliashvili, Francisco Averhoff, Ana Kasradze, Stephanie J Salyer, Giorgi Kuchukhidze, Amiran Gamkrelidze, Paata Imnadze, Maia Alkhazashvili, Gvantsa Chanturia, Nazibrola Chitadze and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Risk factors for HCV infection in Georgia: A case-control study.Journal of infection in developing countries · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. [Seroprevalence and risk factor for hepatitis C in Nogales, Sonora].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Article
  10. Article
  11. Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 3 countries.

Davit BaliashviliNational Center for Disease Control and Public Health, Tbilisi, Georgia.ORCID 0000-0001-8390-3325
Francisco AverhoffDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Ana KasradzeNational Center for Disease Control and Public Health, Tbilisi, Georgia.
Stephanie J SalyerDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0001-7679-2006
Giorgi KuchukhidzeNational Center for Disease Control and Public Health, Tbilisi, Georgia.
Amiran GamkrelidzeNational Center for Disease Control and Public Health, Tbilisi, Georgia.
Paata ImnadzeNational Center for Disease Control and Public Health, Tbilisi, Georgia.
Maia AlkhazashviliNational Center for Disease Control and Public Health, Tbilisi, Georgia.ORCID 0000-0002-1702-2308
Gvantsa ChanturiaNational Center for Disease Control and Public Health, Tbilisi, Georgia.
Nazibrola ChitadzeNational Center for Disease Control and Public Health, Tbilisi, Georgia.ORCID 0000-0002-6910-5447
Roena SukhiashviliNational Center for Disease Control and Public Health, Tbilisi, Georgia.
Curtis BlantonDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Jan DrobeniucDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Juliette MorganDivision of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Liesl M HaganDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
National Center for Disease Control and Public Health · GECenters for Disease Control and Prevention · US

Funding

Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
FIC NIH HHS D43 TW007124
6 · The paper itself

Abstract

In preparation for the National Hepatitis C Elimination Program in the country of Georgia, a nationwide household-based hepatitis C virus (HCV) seroprevalence survey was conducted in 2015. Data were used to estimate HCV genotype distribution and better understand potential sex-specific risk factors that contribute to HCV transmission. HCV genotype distribution by sex and reported risk factors were calculated. We used explanatory logistic regression models stratified by sex to identify behavioral and healthcare-related risk factors for HCV seropositivity, and predictive logistic regression models to identify additional variables that could help predict the presence of infection. Factors associated with HCV seropositivity in explanatory models included, among males, history of injection drug use (IDU) (aOR = 22.4, 95% CI = 12.7, 39.8) and receiving a blood transfusion (aOR = 3.6, 95% CI = 1.4, 8.8), and among females, history of receiving a blood transfusion (aOR = 4.0, 95% CI 2.1, 7.7), kidney dialysis (aOR = 7.3 95% CI 1.5, 35.3) and surgery (aOR = 1.9, 95% CI 1.1, 3.2). The male-specific predictive model additionally identified age, urban residence, and history of incarceration as factors predictive of seropositivity and were used to create a male-specific exposure index (Area under the curve [AUC] = 0.84). The female-specific predictive model had insufficient discriminatory performance to support creating an exposure index (AUC = 0.61). The most prevalent HCV genotype (GT) nationally was GT1b (40.5%), followed by GT3 (34.7%) and GT2 (23.6%). Risk factors for HCV seropositivity and distribution of HCV genotypes in Georgia vary substantially by sex. The HCV exposure index developed for males could be used to inform targeted testing programs.

Indexed as

GenotypeHepatitis CModels, BiologicalAdultFemaleGeorgiaHepacivirusHumansMaleMiddle AgedRisk FactorsSeroepidemiologic Studies

Identifiers

PMID35061841
PMCPMC8782338
OpenAlexW4206477640

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.